Non-small cell lung cancer (NSCLC) includes different subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It’s called “non-small cell” because the cancer cells are larger than small cell lung cancer cells when viewed under a microscope.
NSCLC is common and can spread to other parts of the body. It remains a significant threat, despite progress in treatments.
Efforts to improve early detection methods and lung cancer treatment outcomes are ongoing. The Hightower clinical trial is one initiative exploring new approaches to tackle NSCLC. We are evaluating new drugs and immunotherapy techniques to enhance treatment effectiveness. Furthermore, our oncology clinical trials extend to investigating new biomarkers aimed at streamlining cancer screening processes.